Biologica Technologies has introduced new Allofill at the American Society of Plastic Surgeons (ASPS) meeting in Los Angeles, US.
Allofill is an adipose-derived filler that includes naturally occurring growth factors, which can be used to fill soft-tissue defects as a noninvasive alternative to autologous fat grafting.
The off the shelf filler is said to work with the body to provide all-natural tissue scaffold with native growth factors.
Allofill holds the native extracellular matrix (ECM) components of allograft-derived adipose tissue and will be remodeled into a patient's own soft tissue over time.
Biologica Technologies president and founder Amit Govil said: "We are excited to bring this first of its kind technology to market and provide plastic surgeons a new, unique option as compared to autologous fat transfer (AFT) and the various hyaluronic acid (HA) fillers available on the market.”
The company also produces DermaAMP acellular skin substitute product, which uses firm’s unique processing technology.
DermaAMP will facilitate wound healing through use of the skin’s natural growth factors. It is currently not available for sale in the US.
In addition, the firm produces ProteiOS, which possesses an array of osteoinductive, angiogenic and mitogenic growth factors that can be added to a variety of scaffolds. It helps surgeons to prepare their biologic solution to meet patient’s clinical needs.